ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Janssen Pharmaceuticals, owned by Johnson & Johnson, will get a worldwide, exclusive license to develop a potential nervous system disorder treatment from Pipeline Therapeutics. Pipeline will receive $50 million up front and could get about $1 billion in success-based payments. Pipeline is also getting up to $25 million in equity investments each from a venture capital arm of Johnson & Johnson and from its existing investors. The US Food and Drug Administration has granted Pipeline’s small molecule, a receptor antagonist called PIPE-307, investigational new drug clearance to start clinical trials in people with relapsing-remitting multiple sclerosis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X